Genomic **Product** Passport (GPP) **REACH Business Presentation**

Date: May 2023



Who are We?



Proteineer is a startup that **improves the productivity of industrial biotechnology firms** by facilitating access to (meta)genomic datasets and AI models at massive scale and via an easy-to-use GUI.



Joseph Heenan, CEO
15+ Years Experience in Software
Engineering ranging from Fortune 100 to
lead positions at 3 acquired startups



Aron Eiermann, CTO

Bachelor of Science in Computer Science,
TU Darmstadt. Expert in laboratory
automation software and protein
screening automation.



Johannes Kabisch, CSO
Professor of Biology, Department of
Food Science and Biotechnology, NTNU.
Expert in industrial biotechnology,
creator of pioneering biotechnology
automation and HTS pipelines

What Problem Does GPP Address?




- Accelerating delivery of high-value products using low-cost and environmentally friendly feedstocks in a circular economy
- Development timelines are slow.
- Access to data is a key bottleneck for the industry.
- Genomic product passport facilitating cross-licensing of IP




How Does It Work? Standardized Metadata





How Does It Work? Easy-to-use GUI and Marketplace





Go-To-Market and Sizing



- "The synthetic biology revolution is upon us, and its TRILLIONs of dollars of value to be created" - Eric Schmidt, former CEO, Google
- IP holders to retain control of their data. We profit via brokerage fees for successful transactions
- Integrated public data increases purchaser confidence that they get something better than publicly-available alternatives
- We are developing an open-source standard (GeneLinker.com) participants can trust

Our Business Traction and Partners



Timeline

H1 2022 - Company founded. First Academic collaborations

H2 2022 - First paying customer (publicly-traded chemical manufacturer)

H1 2023 - Further industrial projects, approx 100% revenue growth

H1 2023 - Featured in leading German national print & video media for work in **RNA** manufacturing project

H1 2023 - Accepted into multi—partner industrial consortium for CO2 valorization with approx 1m in software funding (grant-based) expected.









GPP Unlocks Cross-Sectorial Value Chains



A vaccine developer collects a rich dataset of viral sequences looking for novel **RNA** polymerases. It also contains novel **DNA** polymerases he has no use for

DNA polymerases are listed on GeneStore

A diagnostics manufacturer finds them, negotiates a license, and value is unlocked for all parties

Summary



GPP makes it as easy to buy or sell a pair of industrially-useful **blue genes** (used in textile dye manufacturing) as it is to buy or sell a pair of **blue jeans**






Image Credit: https://pubs.acs.org/doi/10.1021/acssuschemeng.0c09341



Thank you for your attention